Patents are legal documents drawn up by inventors and lawyers and granted by various patent offices around the world, to protect the inventors' intellectual property. The short description accompanying each patent in this Patents section is therefore taken from the legal document as is, with minor corrections for Greek symbols and obvious spelling errors. The patents included in this section may be for material products (defensins or defensin-like peptides or nucleic acid sequences, synthetic or natural) or for novel methods of detecting, quantitating, synthesizing, or delivering antimicrobial peptides/nucleic acid sequences in general. The curators' criterion for inclusion in this section is broader for novel methods than for material products, in the hope that these methods may in future be similarly applied to defensins.

Patents in which the defensins or defensin-like material products and methods as above are not novel, such as biomarker sets containing unmodified defensin or defensin-like peptides or oligonucleotides, are excluded from this section. The exception to such exclusions is where the patent provides other novel defensin-related material products or methods in addition to those non-novel of the biomarker set itself. This exclusion is because the reasonable presence of defensin or defensin-like sequences or indeed any other sequences in patented biomarker sets is necessarily attributed to some prior discovery of disease state correlation with such sequences. The curators have observed therefore that the novel discovery in biomarker-related patents is often the method of biomarker array analysis and validation as well as its resultant implications for diagnostics and prognostics. The expert evaluation of such biomarker analysis and validation is well outside the scope of the Defensins Knowledgebase. The reader is respectfully referred to a biomarker database specific to the disease to perform his own assessment of the validity of the biomarker.

Methods not pertaining to the antimicrobial activity of defensins, but where defensins or antimicrobial peptides or small cationic peptides or disulphide-bonded peptides or their respective nucleic acid sequences are suggested in some unambiguous detail to play a useful role in the method, with or without supporting experimental evidence, are included as well in this section. Patents in which natural defensins are up/downregulated in a clearly defined signal transduction pathway as a result of the unrelated patented novel compound or method are also included. And lastly, all patents showing experimental work done with defensins or antimicrobial peptides or small cationic peptides or disulphide-bonded peptides or their respective nucleic acid sequences, where such peptides or nucleic acid sequences are not the experimental controls, are included without exception.

The data in this section have been extracted from the academic version of SciFinder Scholar 2007 and from public Google search - a wide range of defensin-related patents are included.


Results 101 - 110 of 333

<< Previous | 2 | 3 | 4 | 5 | 6 | 7 | 8 | 9 | 10 | 11 | 12 | 13 | 14 | 15 | 16 | 17 | 18 | 19 | 20 | 21 | Next >>

Last updated: 20th February 2008

Patent No.: WO 017985
Multifunctional context-activated protides and methods of use.
Applicant: Yeaman MR, Yount NY, Edwards JE Jr., Brass EP (2004)
This invention is directed to multifunctional, context-activated protides that have two or more effectors with individually distinct biol. functions and one or more corresponding activator sites that can each initiate or amplify the biol. function of one or more effectors upon context-activation. The context-activated protides of the invention are useful in the diagnosis, prophylaxis, and therapy of a broad range of pathol. conditions. A novel invention protide was synthesized that is activated in the context of complement fixation by C3 convertase serine protease activators that cleave the mosaic protide at the cleavage site, liberating the effector domains IL-8 and defensin hNP-1 as independent molecules to effect their respective functions.

Patent No.: WO 003195
Tryptophan or as phenylalanine a functional replacement for ADP-ribose-arginine in recombinant proteins for increasing antimicrobial activities and improving stability.
Applicant: Moss J, Stevens L, Bourgeois C, Bortell R (2004)
A method is disclosed for producing a polypeptide with a modified activity or stability, by replacing an arginine residue capable of being ADP-ribosylated with a tryptophan or a phenylalanine. In one embodiment, compns. are provided that include polypeptides, such as alpha defensin, with arginine-to-tryptophan or arginine-to-phenylalanine substitutions, where the arginine residue is capable of being ADP-ribosylated. In another embodiment, methods are disclosed for modifying an immune response in a subject.

Patent No.: WO 001012
Protein and cDNA sequences of plant defensins and uses for enhancing plant pathogen defense systems.
Applicant: Famodu OO, Herrmann R, Lu AL, McCutchen BF, Miao G-H, Presnail JK, Rafalski JA, Weng Z (2004)
This invention relates to isolated nucleic acids encoding plant defensins and uses for enhancing resistance to plant pathogens. The invention also relates to the construction of a chimeric gene encoding all or a portion of the plant defensin, in sense or antisense orientation, wherein expression of the chimeric gene results in production of altered levels of plant defensins in a transformed host cell.

Patent No.: US 6835822
Diagnosis and therapy of cancer using SGP28-related molecules.
Applicant: Hubert RS, Raitano AB, Afar DEH, Mitchell SC, Faris M, Jakobovits A (2004)
The present invention relates to methods and compositions for the diagnosis and therapy of prostate cancer which utilize isolated polynucleotides corresponding to the human SGP28 gene, proteins encoded by the SGP28 gene and fragments thereof, and antibodies capable of specifically recognizing and binding to SGP28 proteins.

Patent No.: US 6835536
Antimicrobial cationic peptides and formulations thereof.
Applicant: Krieger TJ, McNicol PJ (2004)
Compositions and methods for making and using therapeutic formulations of antimicrobial cationic peptides are provided. The antimicrobial cationic peptide formulations may be used, for example, in the treatment of microorganism-caused infections, which infections may be systemic, such as a septicemia, or may be localized, such as in acne or an implanted or indwelling medical device.

Patent No.: US 6828419
Secreted salivary zsig63 polypeptide.
Applicant: Adler DA, Sheppard PO (2004)
The present invention relates to polynucleotide and polypeptide molecules for zsig63, a novel secreted salivary protein. The polypeptides, and polynucleotides encoding them, may exhibit anti-microbial activity and may be used in the study or treatment of microbial infections. The polynucleotides encoding zsig63, are located on chromosome 4, and can be used to identify a region of the genome associated with human disease states. The present invention also includes antibodies to the zsig63 polypeptides.

Patent No.: US 6821742
Conformational and topological protein regulation.
Applicant: Lingappa VR, Rutkowski DT, Hegde RS (2004)
Methods and compositions are provided for identifying novel conformers of proteins not known to exist as different conformers. By using chimeric genes replacing a native signal sequence with a different signal sequence resulting in the production of a conformer, one can compare the native protein with the product of the chimeric gene. Where the conformations are different, the different protein may be used for production of antibodies, elucidation of mechanisms associated with the native and different conformer protein, assays for the presence of the different conformer in physiological samples, identification of compounds specifically binding to the conformer, particularly drugs, etc. Where the formation of the conformer is associated with a diseased state, the conformer may be used in screens to identify compounds as drug candidates.

Patent No.: US 6818407
Anti-endotoxic antimicrobial cationic peptides and methods of use therfor.
Applicant: Hancock REW, Gough MA, Patrzykat A, Woods D, Jia X (2004)
A novel class of cationic peptides having antimicrobial activity is provided. Exemplary peptides of the invention include KWKSFIKKLTSAAKKVVTTAKPLALIS (SEQ ID NO:3) and KGWGSFFKKAAHVGKHVGKAALTHYL (SEQ ID NO:15). Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Such methods are useful for the treatment of respiratory infections, such as in cystic fibrosis patients. Such methods are further useful for accelerating wound healing.

Patent No.: US 6812217
Medical device and methods of use.
Applicant: Hendriks M (2004)
The present invention provides a medical device that includes a carrier and a polynucleotide, where the carrier has a surface that includes a polymer with which the polynucleotide is associated. In another aspect, the present invention provides a medical device that includes a carrier and a cell that expresses an antimicrobial peptide, where the carrier has a surface that includes a polymer with which the cell is associated. The present invention further provides methods of making and using medical devices that include a carrier and a polynucleotide or a cell.

Patent No.: US 6809181
Human beta-defensin-3 (HBD-3), a highly cationic beta-defensin antimicrobial peptide.
Applicant: McCray PB Jr., Tack BF, Jia HP, Schutte BC (2004)
The present invention relates a novel antimicrobial peptide HBD-3 and derivatives thereof as well as the gene encoding the peptide. The invention further relates to methods of use of the HBD-3 peptide including a method of inhibiting microbial growth by administering an effective amount of the HBD-3 peptide alone or in combinination with other antimicrobial agents or antibiotics. In addition, the immunomodulatory properties of the HBD-3 peptide also facilitate the manipulation of the immune response, i.e., as a chemoattractant for immature dentritic cells or memory T cells.